As of Feb 24
| +0.17 / +4.38%|
The 2 analysts offering 12-month price forecasts for Cascadian Therapeutics Inc have a median target of 14.00, with a high estimate of 15.00 and a low estimate of 13.00. The median estimate represents a +245.68% increase from the last price of 4.05.
The current consensus among 2 polled investment analysts is to Buy stock in Cascadian Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.